[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608614":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":33,"responsibleParty":47,"collaborators":50,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":31,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":85,"overallStatus":96,"whyStopped":31,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Collegium Medicum w Bydgoszczy","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"High platelet reactivity patients receiving rifaximin","EXPERIMENTAL","Participants identified as having high platelet reactivity treated with oral rifaximine",[13],"Drug: Rifaximin",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Rifaximin","Participants receiving a 7-day course of oral rifaximin 400 mg every 12 hours",[9],[21],"Xifaxan",[23],{"name":24,"affiliation":5,"role":25},"Jacek Kubica, Prof.","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Klaudyna Grzelakowska, MD","CONTACT","+48525854023",null,"klaudyna.grzelakowska@gmail.com",[34],{"facility":35,"status":31,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":31},"Cardiology Department, Dr. A. Jurasz University Hospital","Bydgoszcz","Cuiavian-Pomeranian","85-094","Poland","PL",{"type":42,"coordinates":43},"Point",[44,45],18.00762,53.1235,{"lat":45,"lon":44},{"type":25,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Jacek Kubica","Prof.",[51],{"name":52,"class":53},"Ministry of Science and Higher Education, Poland","OTHER_GOV","100608614","phase-4-modulation-of-gut-microflora-with-rifaximin-to-reduce-high-platelet-reactivity-in-post-acs-patients-on-ticagrelor-100608614",false,"NCT07203846","Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor","Modulation of Gut Microflora With Rifaximin to Reduce High Platelet Reactivity in Post-Acute Coronary Syndrome Patients on Ticagrelor (FLORA-ACS)","FLORA-ACS","Inclusion criteria:\n\n* Between 18 and 80 years of age\n* History of acute coronary syndrome no sooner than 1 month and no later than 12 months prior to study inclusion\n* Current treatment with ticagrelor (90 mg orally twice a day)\n* High platelet reactivity assessed with multiple electrode aggregometry method (AUC of \\>46 U)\n* Provision of informed consent prior to any study procedures\n\nExclusion criteria:\n\n* History of hypersensitivity to rifaximin or other rifamycin-derived agent\n* Ongoing treatment with rifamycins\n* Platelet count \\\u003C 100×10\\^9\u002FL or \\> 450×10\\^9\u002FL\n* Treatment with antibiotics, probiotics, or glucocorticoids within 3 months prior to study inclusion\n* History of gastrointestinal diseases such as inflammatory bowel disease, bowel obstruction, or gastrointestinal tumor\n* Infection, including gastrointestinal infection, within a month prior to study inclusion\n* History of Clostridium difficile infection\n* Current use of specific medications (warfarin, glycoprotein IIb\u002FIIIa inhibitors, immunosuppressants, bile acid sequestrants, antidiarrheal agents)\n* Impaired liver function classified as Child-Pugh class B or C\n* Hemodynamic instability\n* Pregnancy or breastfeeding\n* Patients considered by the investigator to be uncooperative","ALL","18 Years","80 Years",{"count":66,"type":67},50,"ESTIMATED","INTERVENTIONAL",[70],"PHASE4","The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.",[73,74,75,76,77,78,79,80,81,82,83,84,17],"ACS - Acute Coronary Syndrome","Ticagrelor","Microbiota","Platelet Aggregation","Myocardial Infarction (MI)","Blood Platelets","Drug Effects","Platelet Aggregation Inhibitors","Drug Resistance","Platelet Function Tests","Dysbiosis","Anti-Bacterial Agents",[86,87,88,89,90,91,92,93,94,95],"high platelet reactivity","HPR","Multiplate aggregometry","multiple electrode aggregometry","MEA","microbiome","gut flora","eubiotic","16S rRNA sequencing","P2Y12 inhibitor","NOT_YET_RECRUITING","2025-09-25",{"date":99,"type":100},"2025-10-02","ACTUAL",{"date":102,"type":67},"2026-01-01",{"date":104,"type":67},"2027-06-30",{"name":5,"class":6},1]